The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review

2019 ◽  
Vol 43 (3) ◽  
pp. 118-123
Author(s):  
D. Lorente ◽  
E. Trilla ◽  
A. Meseguer ◽  
J. Arevalo ◽  
S. Nemours ◽  
...  
Keyword(s):  
Systematic Review ◽  
Prognostic Factor ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma

scholarly journals Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma

2009 ◽  
Vol 125 (10) ◽  
pp. 2307-2315 ◽  
Author(s):  
Jean-Laurent Deville ◽  
Catherine Bartoli ◽  
Caroline Berenguer ◽  
Samantha Fernandez-Sauze ◽  
Itidal Kaafarani ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Renal Tumors ◽  
Mrna Levels ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma

MP16-01 ROLE OF FGFR4 IN CLEAR CELL RENAL CARCINOMA AND ITS POTENTIAL AS A NEW THERAPEUTIC TARGET

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Takafumi Narisawa* ◽  
Sei Naito ◽  
Hiromi Ito ◽  
Toshihiko Sakurai ◽  
Osamu Ichiyanagi ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma

scholarly journals Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

2020 ◽  
Vol 12 ◽  
pp. 175883592091530
Author(s):  
Melissa Bersanelli ◽  
Matteo Brunelli ◽  
Letizia Gnetti ◽  
Umberto Maestroni ◽  
Sebastiano Buti
Keyword(s):  
Systematic Review ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Therapeutic Option ◽  
Comparable Efficacy ◽  
Line Treatment ◽  
Clear Cell Renal Carcinoma ◽  
First Line ◽  
Cell Renal Carcinoma ◽  
First Line Treatment

Background: Effective systemic treatment of non-clear cell renal carcinoma (nccRCC) is still an unmet clinical need, with few studies to support an evidence-based approach. To date, the only recommended standard first-line treatment is sunitinib. Pazopanib may also be used in nccRCC but its place in therapy is not clearly established. It has comparable efficacy and better tolerability than sunitinib in clear cell renal carcinoma. Our objective was to review the use of pazopanib in metastatic nccRCC. Methods: We conducted a systematic review according to PRISMA guidelines. Any type of study reporting the use of pazopanib in metastatic renal cell carcinoma including cases with non-clear cell histology was eligible. Results: In all, 15 studies were included in our analysis, including a total of 318 nccRCC patients treated with pazopanib. Most studies were retrospective ( n = 12); three were prospective trials. The specific outcomes of nccRCC patients were reported by four studies. Pazopanib alone as first-line treatment gave overall response rates ranging from 27% to 33%, disease control rates of 81–89%, median progression free survival of 8.1–16.5 months and median overall survival of 17.3–31.0 months. Grade 3–4 adverse events rates were 21–55%. Conclusion: The present review provides for the first time a systematic summary of evidence about the possible use of pazopanib as first-line treatment for nccRCC, with a favorable outcome despite the low strength of evidence. Pazopanib could be considered as a possible therapeutic option in this setting.

Expression and Proliferation-Promoting Role of Lymphoid Enhancer-Binding Factor 1 in Human Clear Cell Renal Carcinoma

2014 ◽  
Vol 32 (7) ◽  
pp. 368-374 ◽  
Author(s):  
Donghao Shang ◽  
Rumei Bi ◽  
Tiandong Han ◽  
Daye Wang ◽  
Ye Tian ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
Binding Factor ◽  
Cell Renal Carcinoma
Sign in / Sign up

Export Citation Format

Share Document